CymaBay Therapeutics (NASDAQ:CBAY) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of CymaBay Therapeutics (NASDAQ:CBAY) in a report released on Monday. The firm issued a sell rating on the biopharmaceutical company’s stock.

A number of other equities research analysts also recently commented on the company. Jonestrading restated a hold rating on shares of CymaBay Therapeutics in a research report on Tuesday, February 13th. B. Riley restated a neutral rating and issued a $32.50 target price (up previously from $29.00) on shares of CymaBay Therapeutics in a research report on Tuesday, February 13th. SVB Leerink reiterated a market perform rating and issued a $32.50 price objective on shares of CymaBay Therapeutics in a report on Tuesday, February 20th. UBS Group reiterated a neutral rating and issued a $32.50 price objective (up previously from $25.00) on shares of CymaBay Therapeutics in a report on Wednesday, February 14th. Finally, Raymond James downgraded CymaBay Therapeutics from an outperform rating to a market perform rating and set a $32.50 price objective on the stock. in a report on Tuesday, February 13th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat, CymaBay Therapeutics has an average rating of Hold and an average target price of $28.65.

CymaBay Therapeutics Stock Performance

Shares of CymaBay Therapeutics stock opened at $32.48 on Monday. CymaBay Therapeutics has a one year low of $7.26 and a one year high of $32.50. The company has a market cap of $3.73 billion, a price-to-earnings ratio of -33.48 and a beta of 0.32. The business’s 50 day moving average price is $29.62 and its 200 day moving average price is $22.29.

CymaBay Therapeutics (NASDAQ:CBAY) last announced its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.04). The company had revenue of $0.06 million during the quarter, compared to analysts’ expectations of $0.42 million. On average, analysts predict that CymaBay Therapeutics will post -1.38 EPS for the current fiscal year.

Insider Transactions at CymaBay Therapeutics

In other news, insider Charles Mcwherter sold 18,403 shares of the firm’s stock in a transaction on Friday, January 19th. The stock was sold at an average price of $23.67, for a total transaction of $435,599.01. Following the sale, the insider now owns 15,000 shares in the company, valued at $355,050. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, insider Charles Mcwherter sold 18,403 shares of the firm’s stock in a transaction dated Friday, January 19th. The stock was sold at an average price of $23.67, for a total transaction of $435,599.01. Following the completion of the sale, the insider now directly owns 15,000 shares in the company, valued at $355,050. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Daniel Menold sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $23.58, for a total value of $235,800.00. The disclosure for this sale can be found here. Insiders have sold 45,403 shares of company stock worth $1,124,279 over the last quarter. 7.00% of the stock is currently owned by insiders.

Institutional Trading of CymaBay Therapeutics

Several large investors have recently modified their holdings of CBAY. RA Capital Management L.P. acquired a new stake in shares of CymaBay Therapeutics during the third quarter valued at about $103,475,000. BlackRock Inc. grew its stake in CymaBay Therapeutics by 183.2% in the second quarter. BlackRock Inc. now owns 7,504,670 shares of the biopharmaceutical company’s stock worth $82,176,000 after purchasing an additional 4,854,593 shares in the last quarter. Franklin Resources Inc. grew its stake in CymaBay Therapeutics by 13,862.3% in the first quarter. Franklin Resources Inc. now owns 3,224,862 shares of the biopharmaceutical company’s stock worth $28,121,000 after purchasing an additional 3,201,765 shares in the last quarter. Perceptive Advisors LLC grew its stake in CymaBay Therapeutics by 450.5% in the first quarter. Perceptive Advisors LLC now owns 3,903,255 shares of the biopharmaceutical company’s stock worth $34,036,000 after purchasing an additional 3,194,262 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its stake in CymaBay Therapeutics by 134.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,465,161 shares of the biopharmaceutical company’s stock worth $105,468,000 after purchasing an additional 2,561,460 shares in the last quarter. 95.03% of the stock is currently owned by institutional investors and hedge funds.

CymaBay Therapeutics Company Profile

CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC).